Neuregulin Antagonists and Use Thereof in Treating Cancer

A method of using neuregulin antagonists to delay the time of tumor recurrence in cancer patients has been developed by Dr. Sweet-Cordero and collaborators. This technology is available for non-exclusive license. For many cancer patients disease recurrence after chemotherapy is a major cause of mortality. This relapse and recurrence is caused by tumor-reinitiating cells (TRICs). Neuregulin autocrine signaling plays an important role in the survival and proliferation of TRICs, thus antagonizing neuregulin signaling can delay the time to tumor recurrence.